Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RGS12 | O14924 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974813 | 0.88 | RGS12 (0.36) | RGS12TSHRALDH1A1HTTIDO1 | |
| SCHEMBL854904 | 0.86 | RGS12 (0.37) | RGS12TSHRALDH1A1HTTIDO1 | |
| SCHEMBL854710 | 0.83 | RGS12 (0.33) | RGS12TSHRALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL7262368 | 0.81 | LMNA (0.38) | RGS12TSHRALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6250456 | 0.80 | TSHR (0.40) | RGS12TSHRALDH1A1HTTTDP1 | |
| SCHEMBL11420895 | 0.80 | TSHR (0.40) | RGS12TSHRALDH1A1HTTTDP1 | |
| SCHEMBL4622448 | 0.80 | RGS12 (0.33) | RGS12TSHRALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL6534572 | 0.76 | RGS12 (0.34) | RGS12TSHRALDH1A1HTTSMN1; SMN2 | |
| SCHEMBL11537769 | 0.75 | TSHR (0.47) | RGS12TSHRALDH1A1HTT | |
| SCHEMBL9862315 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420683-B2 | 5 substituted hydantoins | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2013-04-16 | — | — | US | disclosed |
| EP-2150538-B1 | NOVEL 5-SUBSTITUTED HYDANTOINS | DSM SINOCHEM PHARM NL BV (NL) | 2012-03-28 | — | — | EP | disclosed |
| EP-2267144-A2 | Whole-cell catalytic system comprising a hydantoinase, a racemase and a carbamoylase | DSM IP Assets B.V. (NL) | 2010-12-29 | — | — | EP | disclosed |
| US-20100174092-A1 | NOVEL 5 SUBSTITUTED HYDANTOINS | DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) | 2010-07-08 | — | — | US | disclosed |
| EP-2150538-A2 | NOVEL 5-SUBSTITUTED HYDANTOINS | DSM IP Assets B.V. (NL) | 2010-02-10 | — | — | EP | disclosed |
| EP-2102353-A2 | WHOLE-CELL CATALYTIC SYSTEM COMPRISING A HYDANTOINASE, A RACEMASE AND A CARBAMOYLASE | DSM IP Assets B.V. (NL) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008148755-A2 | NOVEL 5-SUBSTITUTED HYDANTOINS | DSM IP ASSETS B.V. (NL) | 2008-12-11 | — | — | WO | disclosed |
| WO-2008067981-A2 | WHOLE-CELL CATALYTIC SYSTEM COMPRISING A HYDANTOINASE, A RACEMASE AND A CARBAMOYLASE | DSM IP ASSETS B.V. (NL) | 2008-06-12 | — | — | WO | disclosed |
| US-4237227-A | ENZYMATIC HYDROLYSIS OF A HYDANTOIN | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1980-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100174092-A1 | NOVEL 5 SUBSTITUTED HYDANTOINS | CYP3A5, REN, ACE | RGS12 863/4885TSHR 4789/4885ALDH1A1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.